Isoflavones and the prevention and treatment of prostate disease: Is there a role?

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 3, 2003, Pages 203-216

  Gaynor, Mitchell Lee ^a,b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b Medical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; BASIC SOY ISOFLAVONES; BETA CAROTENE; BIOCHANIN A; CARLSON EASY SOY; CARLSON EASY SOY GOLD; DAIDZEIN; DUTASTERIDE; ERDIC; ESTROGEN RECEPTOR; ESTROVEN; FINASTERIDE; FORMONECTIN; GENISTEIN; H AND B SOYA ISOFLAVONES; HEALTHY WOMAN; HERBAL BLENDS MENOPAUSE BALANCE; HYPOCHOLESTEROLEMIC AGENT; ISOFLAVONE DERIVATIVE; KUDZU ROOT EXTRACT; N RESOURCES SOY ISOFLAVONES; NATURALLY PREFERRED SOY GERM; NATURES BOUNTY FLASH FIGHTERS; NEOARSPHENAMINE; NEW PHASE SUNSOURCE; NICOTINIC ACID; NOVASOY; NUTRI SOY; ONE A DAY; PHYTO ESTROGEN POWER; PHYTO SOYA; PHYTOESTRIN; PHYTOESTROGEN; PHYTOESTROGEN SOLARAY; PHYTOSOY; POLYPHENOL DERIVATIVE; SELENIUM; SIMVASTATIN; SOLGAR; SOY CARE; SOY CHOICE VITANICA; SOY EXTRACT; SOY LIFE 25; SOY PLUS; SOYAMAX; SOYBEAN OIL; SPRING VALLEY; SUNDOWN; TAMSULOSIN; TERAZOSIN; TRINOVIN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET SUPPLEMENTATION; DROWSINESS; DRUG ABSORPTION; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; HUMAN; HYPOTENSION; IMPOTENCE; LEGUME; MALE; NONHUMAN; NOSE CONGESTION; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SOYBEAN; VERTIGO;

EID: 0037366528     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.3.203     Document Type: Review

References (61)

1. Griffiths K, Denis L, Turkes A, Morton MS. Phytoestrogens and diseases of the prostate gland. Baillieres Clin Endocrinol Metab 1998; 12:625-647.
2. Boyle P. New insights into the epidemiology and natural history of benign prostatic hyperplasia. Prog Clin Biol Res 1994; 386:3-18.
3. The Department of Veterans Affairs Cooperative Study of Transurethral Resection for Benign Prostatic Hyperplasia. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. J Urol 1993; 150:1696-1700.
4. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993; 150(2 pt 1):351-358.
5. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG, for the Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995; 332:75-79.
6. Graversen PH, Gasser TC, Wasson JH, Hinman F Jr, Bruskewitz RC. Controversies about indications for transurethral resection of the prostate. J Urol 1989; 141:475-481.
7. Schelin S. Microwave thermotherapy in patients with benign prostatic hyperplasia and chronic urinary retention. Eur Urol 2001; 39:400-404.
8. Floratos DL, Kiemeney LA, Rossi C, Kortmann BB, Debruyne FM, de la Rosette JJ. Long-term follow-up of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 2001; 165:1533-1538.
9. Syed AH, Stewart LH, Hargreave TB. Day-case local anaesthetic radiofrequency thermal ablation of benign prostatic hyperplasia: a four-year follow-up. Scand J Urol Nephrol 2000; 34:309-312.
10. Wada S, Yoshimura R, Kyo M, et al. Comparative study of transurethral laser prostatectomy versus transurethral electroresection for benign prostatic hyperplasia. Int J Urol 2000; 7:373-377.
11. Puppo P. Long-term effects on BPH of medical and instrumental therapies. Eur Urol 2001; 39(suppl 6):2-6.
12. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). CMAJ 1996; 155:1251-1259.
13. HYTRIN [manufacturer's prescribing information]. North Chicago, III: Abbott Laboratories; 1996.
14. FLOMAX [manufacturer's prescribing information]. Ridgefield, Conn: Boehringer Ingelheim Pharmaceuticals, Inc; 1995.
15. PROSCAR [manufacturer's prescribing information]. West Point, Pa: Merck & Co, Inc; 1998.
16. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993; 328:246-252.
17. Intersociety Professional Nutrition Education Consortium. Bringing physician nutrition specialists into the mainstream: rationale for the Intersociety Professional Nutrition Education Consortium. Am J Clin Nutr 1998; 68:894-898.
18. Weinsier RL, Boker JR, Feldman EB, Read MS, Brooks CM. Nutrition knowledge of senior medical students: a collaborative study of southeastern medical schools. Am J Clin Nutr 1986; 43:959-968.
19. Kelly G. Benign Prostatic Hypertrophy, Prostate Cancer and Isoflavones. Stamford, Conn: Novogen, Inc; 1999.
20. Song T, Barua K, Buseman G, Murphy PA. Soy isoflavone analysis: quality control and a new internal standard. Am J Clin Nutr 1998; 68(suppl 6):1474S-1479S.
21. Day AJ, Cañada FJ, Diaz JC, et al. Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett 2000; 468:166-170.
22. Setchell KD. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 1998; 68(suppl 6):1333S-1346S.
23. Evans BA, Griffiths K, Morton MS. Inhibition of 5α-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 1995; 147:295-302.
24. Keung WM. Dietary estrogenic isoflavones are potent inhibitors of β-hydroxysteroid dehydrogenase of P. testosteronii. Biochem Biophys Res Commun 1995; 215:1137-1144.
25. Sun XY, Plouzek CA, Henry JP, Wang TT, Phang JM. Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells. Cancer Res 1998; 58:2379-2384.
26. Weisser H, Krieg M. [Benign prostatic hyperplasia-the outcome of age-induced alteration of androgen-estrogen balance?] Urologe A 1997; 36:3-9.
27. Matzkin H, Soloway MS. Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues. Prostate 1992; 21:309-314.
28. Habenicht UF, el Etreby MF. Selective inhibition of androstenedione-induced prostate growth in intact beagle dogs by a combined treatment with the antiandrogen cyproterone acetate and the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione (1-methyl-ADD). Prostate 1989; 14:309-322.
29. Campbell DR, Kurzer MS. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J Steroid Biochem Mol Biol 1993; 46:381-388.
30. Collins BM, McLachlan JA, Arnold SF. The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast. Steroids 1997; 62:365-372.
31. Miksicek RJ. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 1993; 44:37-43.
32. Wang TT, Sathyamoorthy N, Phang JM. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 1996; 17:271-275.
33. Bødker A, Bruun J, Balslev E, Iversen H-G, Meyhoff H-H, Andersson K-E. Estrogen receptors in the human male prostatic urethra and prostate in prostatic cancer and benign prostatic hyperplasia. Scand J Urol Nephrol 1999; 33:237-242.
34. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 1999; 155:641-647.
35. Theyer G, Schirmböck M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 1993; 150(5 pt 1):1544-1547.
36. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J-Å, Nilsson S. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 1998; 54:105-112.
37. Casanova M, You L, Gaido KW, Archibeque-Engle S, Janszen DB, Heck HA. Developmental effects of dietary phytoestrogens in Sprague-Dawley rats and interactions of genistein and daidzein with rat estrogen receptors α and β in vitro. J Toxicol Sci 1999; 51:236-244.
38. Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993; 22:335-345.
39. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262:5592-5595.
40. Dalu A, Haskell JF, Coward L, Lamartiniere CA. Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate. Prostate 1998; 37:36-43.
41. Wei H, Bowen R, Cai Q, Barnes S, Wang Y. Antioxidant and antipromotional effects of the soybean isoflavone genistein. Proc Soc Exp Biol Med 1995; 208:124-130.
42. Jha HC, von Recklinghausen G, Zilliken F. Inhibition of in vitro microsomal lipid peroxidation by isoflavonoids. Biochem Pharmacol 1985; 34:1367-1369.
43. Bergan R, Kyle E, Nguyen P, Trepel J, Ingui C, Neckers L. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to β1-integrin. Clin Exp Metastasis 1996; 14:389-398.
44. Fotsis T, Pepper M, Adlercreutz H, Hase T, Montesano R, Schweigerer L. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr 1995; 125(suppl 3):790S-797S.
45. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993; 342:1209-1210.
46. Morton MS, Chan PS, Cheng C, et al. Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom. Prostate 1997; 32:122-128.
47. Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer: geographical distribution and time-trends. Acta Oncol 1991; 30:133-140.
48. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991; 63:963-966.
49. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998; 9:553-557.
50. Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989; 64:598-604.
51. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 1998; 90:1637-1647.
52. Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS, Ewing LL. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 1992; 43:557-564.
53. Pollard M, Luckert PH. Influence of isoflavones in soy protein isolates on development of induced prostate-related cancers in L-W rats. Nutr Cancer 1997; 28:41-45.
54. Stephens FO. Phytoestrogens and prostate cancer: possible preventive role. Med J Aust 1997; 167:138-140.
55. Gaynor ML, Hickey J. Soy and genistein. In: Dr. Gaynor's Cancer Prevention Program. New York, NY: Kensington Publishing; 1999:89-100.
56. Chen Z, Zheng W, Custer U, et al. Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shanghai. Nutr Cancer 1999; 33:82-87.
57. Setchell KDR, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001; 131:1362S-1375S.
58. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029-1035.
59. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150-1155.
60. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342:154-160.
61. Brown BG, Zhao ZQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592.